Lung cancer immunotherapy: progress, pitfalls, and promises.
Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. · 2023
Read Lung cancer immunotherapy: progress, pitfalls, and promises. by Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9942077.txt.
Introduction
Lahiri and co-authors track progress and pitfalls in lung cancer immunotherapy. Lung cancer is the top cause of cancer death in the United States and worldwide. Standard care spans surgery, radiation, chemotherapy, and targeted drugs. Resistance and relapse limit those options.
Immunotherapy offers durable gains through immune memory and a mild safety profile. Checkpoint blockade against PD-1 and PD-L1 gave strong, lasting responses in many patients. The review covers tumor vaccines and adoptive cell methods such as CAR T, TCR, and TIL therapy. Trial results and hurdles for each route are discussed. Loss of antitumor immunity tracks with tumor growth. The authors argue that vaccines plus checkpoint drugs can do better together.
Catalog record
| CREATOR | Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 192 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |